.Competing rate of interests.R.S., M.S., H.G. as well as A.A.R. are actually coordinators of the 1M1M initiative.
H.G. and A.A.R. are actually board of supervisors members as well as R.S., M.S.
and A.A.R. are members of the scientific advising board of N1C. A.A.R.
reveals work through LUMC, which possesses patents on exon-skipping innovation, a number of which has actually been actually accredited to BioMarin and ultimately sublicensed to Sarepta. As co-inventor of some of these licenses, A.A.R. was actually qualified to a share of aristocracies.
A.A.R. even further reveals acting as expert for PTC Therapeutics, Sarepta Therapies, Regenxbio, Dyne Therapies, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco as well as Astra Zeneca. Before 5 years, A.A.R.
also performed speaking with for Alpha Anomeric. A.A.R. likewise discloses membership of the medical advisory boards of Eisai, Hybridize Therapeutics, Muteness Therapies, Sarepta Rehabs, Sapreme and also Mitorx.
In the past 5 years, A.A.R. was actually likewise a medical advisory board member for ProQR. Compensation for A.A.R.
u00e2 s consulting and advising activities is paid to LUMC. Previously 5 years, LUMC likewise obtained audio speaker honoraria from PTC Rehabs, Alnylam Netherlands, Italfarmaco and also Pfizer as well as moneying for arrangement analysis coming from Sapreme, Eisai, Galapagos, Synaffix and Alpha Anomeric. Job financing is gotten coming from Sarepta Therapies as well as Entrada using unlimited grants.
H.G. has nothing at all to disclose relative to the topics covered in this particular manuscript. Over the last 5 years, he has also obtained consultancy honoraria coming from UCB.
M.S. acquired working as a consultant honoraria coming from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly and Solaxa over the last 5 years, all unassociated to the here and now manuscript. R.S.
possesses absolutely nothing to make known in connection with the subject matters dealt with in this manuscript. She has actually acquired sound speaker and/or consultancy honoraria or funding additions from Abbvie, Bial, STADA and Everpharma previously 5 years.